Edition:
United Kingdom

Steadymed Ltd (STDY.OQ)

STDY.OQ on NASDAQ Stock Exchange Global Market

2.90USD
20 Apr 2018
Change (% chg)

-- (--)
Prev Close
$2.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,862
52-wk High
$7.45
52-wk Low
$2.80

Chart for

About

SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH). It is also developing... (more)

Overall

Beta: --
Market Cap(Mil.): $84.98
Shares Outstanding(Mil.): 26.56
Dividend: --
Yield (%): --

Financials

  STDY.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.94 -- --
ROI: -128.53 1.58 14.38
ROE: -221.79 2.41 16.07

BRIEF-Steadymed Reports Q4 Loss Per Share $0.22

* Q4 LOSS PER SHARE $0.22 Source text : http://bit.ly/2Gov1vO Further company coverage:

30 Mar 2018

BRIEF-SteadyMed Announces FDA Agreed Pathway To Trevyent NDA Resubmission

* STEADYMED ANNOUNCES FDA AGREED PATHWAY TO TREVYENT NDA RESUBMISSION

08 Dec 2017

BRIEF-STEADYMED RECEIVES FAVORABLE RULING FROM U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT

* ‍COURT OF APPEALS AFFIRMED A MARCH 31 RULING BY PATENT TRIAL & APPEAL BOARD INVALIDATING U.S. PATENT NO 8,497,393 OWNED BY UNITED THERAPEUTICS​

14 Nov 2017

BRIEF-Steadymed reports Q3 earnings per share $0.35

* Steadymed reports third quarter 2017 financial results and provides corporate update

13 Nov 2017

Earnings vs. Estimates